Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.70 |
| ▸ | S1PR1 | P21453 | 5/20 | 0.67 |
| ▸ | S1PR3 | Q99500 | 3/20 | 0.67 |
| ▸ | S1PR2 | O95136 | 3/20 | 0.67 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.65 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.65 |
| ▸ | CYSLTR2 | Q9NS75 | 1/20 | 0.63 |
| ▸ | CYSLTR1 | Q9Y271 | 1/20 | 0.63 |
| ▸ | RARB | P10826 | 5/20 | 0.62 |
| ▸ | MEN1 | O00255 | 1/20 | 0.62 |
| ▸ | RARA | P10276 | 1/20 | 0.62 |
| ▸ | MAPT | P10636 | 1/20 | 0.62 |
| ▸ | MTOR | P42345 | 1/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.62 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.61 |
| ▸ | HPGD | P15428 | 1/20 | 0.61 |
| ▸ | ESR1 | P03372 | 2/20 | 0.60 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.60 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.60 |
| ▸ | TACR2 | P21452 | 2/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6286434 | 1.00 | ALDH1A1 (0.70) | ALDH1A1S1PR1S1PR3S1PR2FFAR1 | |
| SCHEMBL6288014 | 1.00 | ALDH1A1 (0.70) | ALDH1A1S1PR1S1PR3S1PR2FFAR1 | |
| SCHEMBL10435207 | 1.00 | ALDH1A1 (0.70) | ALDH1A1S1PR1S1PR3S1PR2FFAR1 | |
| SCHEMBL20854085 | 1.00 | ALDH1A1 (0.70) | ALDH1A1S1PR1S1PR3S1PR2FFAR1 | |
| SCHEMBL6285855 | 0.98 | ALDH1A1 (0.72) | ALDH1A1S1PR1S1PR3S1PR2FFAR1 | |
| SCHEMBL7338362 | 0.95 | RARB (0.71) | ALDH1A1S1PR1S1PR3S1PR2FFAR1 | |
| SCHEMBL31270921 | 0.95 | RARB (0.71) | ALDH1A1S1PR1S1PR3S1PR2FFAR1 | |
| SCHEMBL7338308 | 0.93 | RARB (0.70) | ALDH1A1S1PR1S1PR3S1PR2FFAR1 | |
| SCHEMBL25170021 | 0.92 | S1PR1 (0.71) | ALDH1A1S1PR1S1PR3S1PR2FFAR1 | |
| SCHEMBL6151349 | 0.92 | S1PR1 (0.71) | ALDH1A1S1PR1S1PR3S1PR2CYSLTR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2343306-B1 | Glycolipid derivatives, process for production of the same, intermediates for synthesis thereof, and process for production of the intermediates | JAPAN PRESIDENT NAT CT NEUROLOGY & PSYCHIATRY (JP) | 2018-04-04 | — | — | EP | disclosed |
| US-8034908-B2 | Glycolipids and synthetic method thereof as well as their synthetic intermediates, and synthetic method thereof | JAPAN AS REPRESENTED BY PRESIDENT OF NATIONAL CENTER OF NEUROLOGY AND PSYCHIATRY (JP) | 2011-10-11 | — | — | US | disclosed |
| EP-2343306-A1 | Glycolipid derivatives, process for production of the same, intermediates for synthesis thereof, and process for production of the intermediates | Japan as represented by President of National Center of Neurology and Psychiatry Ministry of Health (JP) | 2011-07-13 | — | — | EP | disclosed |
| CN-101165047-B | Glycolipid derivative and its manufacturing method, and its synthesizing intermediate and its manufacturing method | DAIICHI ASUBIO PHARMA CO LTD (JP) | 2010-10-20 | — | — | CN | disclosed |
| US-20100210828-A1 | NEW GLYCOLIPIDS AND SYNTHETIC METHOD THEREOF AS WELL AS THEIR SYNTHETIC INTERMEDIATES, AND SYNTHETIC METHOD THEREOF | JAPAN AS REPRESENTED BY THE PRESIDENT OF NATIONAL CENTER OF NEUROLOGY AND PSYCHIATRY (JP) | 2010-08-19 | — | — | US | disclosed |
| US-7732583-B2 | Glycolipids and synthetic method thereof as well as their synthetic intermediates, and synthetic intermediates, and synthetic method thereof | JAPAN AS REPRESENTED BY PRESIDENT OF NATIONAL CENTER OF NEUROLOGY AND PSYCHIATRY (JP) | 2010-06-08 | — | — | US | disclosed |
| CN-100537585-C | Glycolipid derivative, process for producing the same, intermediate for the synthesis thereof, and process for producing the same | DAIICHI SUNTORY PHARMA CO LTD (JP) | 2009-09-09 | — | — | CN | disclosed |
| CN-101165047-A | Glycolipid derivative and its manufacturing method, and its synthesizing intermediate and its manufacturing method | DAIICHI ASUBIO PHARMA CO LTD (JP) | 2008-04-23 | — | — | CN | disclosed |
| CN-1768072-A | Glycolipid derivative, process for producing the same, intermediate for the synthesis thereof, and process for producing the same | DAIICHI SUNTORY PHARMA CO LTD (JP) | 2006-05-03 | — | — | CN | disclosed |
| US-20060074235-A1 | Glycolipids derivatives, process for production of the same, intermediates for synthesis thereof, and process for production of the intermediates | JAPAN AS REPRESENTED BY PRESIDENT OF NATIONAL CENTER OF NEUROLOGY AND PSYCHIATRY (JP) | 2006-04-06 | — | — | US | disclosed |
| EP-1619199-A1 | GLYCOLIPID DERIVATIVES, PROCESS FOR PRODUCTION OF THE SAME, INTERMEDIATES FOR SYNTHESIS THEREOF, AND PROCESS FOR PRODUCTION OF THE INTERMEDIATES | Daiichi Asubio Pharma Co., Ltd. (JP) | 2006-01-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100210828-A1 | NEW GLYCOLIPIDS AND SYNTHETIC METHOD THEREOF AS WELL AS THEIR SYNTHETIC INTERMEDIATES, AND SYNTHETIC METHOD THEREOF | SGMS1, UGCG, SGMS2 | ALDH1A1 3936/4885S1PR1 12/4885S1PR3 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.